With the domestic market looking to be phenomenal over the next two-three years, the company is investing about Rs 130 crores in its research facility, over the same period. Last year, the research facility was upgraded to focus on developing new drug delivery systems. In the second year, the team has been increased and will work on developing products to be marketed by the company and its in-licensing partners.
The company has about 25 licensing partners, whose products Elder Pharma sells in India. The company is undertaking collaborative research work in some of these partnerships. Elder Pharma's area of focus includes prescription products in women's health, nutraceuticals and pain management. At present, wound care and pain management contribute about 16 per cent to Elder's turnover and is anticipated to grow at over 15 per cent every year. Elder's products include its Rs 200-crore Shelcal, now set to be taken to Sri Lanka and Bangladesh, among other markets.
Last year, saw Elder Pharma hike its stake in UK's Neutra Health Plc to 100 per cent, besides holding 92 per cent equity in Elder Biomeda of Bulgaria. Both operations will contribute about 25 per cent of the turnover this year. The focus will be on Bulgaria, which will later be used as an access market into Europe. The plan is also to support Neutra products through different pricing, adding that they would at a later stage look at bringing some of their products into India, as well. The company looks to clock consolidated revenues of about Rs 1,300 crores, this fiscal
| Company Name | CMP |
|---|---|
| Sun Pharma Inds. | 1847.30 |
| Dr. Reddys Lab | 1293.25 |
| Cipla | 1347.70 |
| Zydus Lifesciences | 938.90 |
| Lupin | 2377.90 |
| View more.. | |
MoneyWorks4Me is a SEBI-registered Investment Adviser (IA) dedicated to helping investors build long-term wealth through transparent, research-driven, conflict-free guidance. Founded in 2008, we started our journey as a Research Analyst (RA), providing deep fundamental analysis, intrinsic value insights, and long-term investing frameworks for Indian equities. In 2017, we transitioned to a full-fledged SEBI-registered Investment Adviser, strengthening our commitment to acting as a fiduciary—always putting the investor’s interest first.
To become India’s most trusted, research-powered fiduciary advisory platform—where every investor, regardless of experience, can make calm, confident, and well-reasoned investment decisions.
MoneyWorks4Me ensures this through: